Abbisko Cayman Limited

DB:8ZD Stock Report

Market Cap: €551.2m

Abbisko Cayman Valuation

Is 8ZD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8ZD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€0.59
Fair Value
43.8% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: 8ZD (€0.85) is trading above our estimate of fair value (€0.59)

Significantly Below Fair Value: 8ZD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8ZD?

Key metric: As 8ZD is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 8ZD. This is calculated by dividing 8ZD's market cap by their current revenue.
What is 8ZD's PS Ratio?
PS Ratio8.9x
SalesCN¥503.99m
Market CapCN¥4.48b

Price to Sales Ratio vs Peers

How does 8ZD's PS Ratio compare to its peers?

The above table shows the PS ratio for 8ZD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8x
FYB Formycon
6.2x18.4%€433.5m
2INV 2invest
2.7xn/a€68.9m
BIO3 Biotest
1.6xn/a€1.4b
HPHA Heidelberg Pharma
21.6x39.7%€147.7m
8ZD Abbisko Cayman
8.9x9.6%€4.8b

Price-To-Sales vs Peers: 8ZD is expensive based on its Price-To-Sales Ratio (8.9x) compared to the peer average (8x).

Price to Sales Ratio vs Industry

How does 8ZD's PS Ratio compare vs other companies in the DE Biotechs Industry?

9 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.6xn/aUS$1.61b
2INV 2invest
2.7xn/aUS$77.38m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
8ZD 8.9xIndustry Avg. 7.5xNo. of Companies9PS01224364860+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 8ZD is expensive based on its Price-To-Sales Ratio (8.9x) compared to the European Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 8ZD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8ZD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.9x
Fair PS Ratio2.2x

Price-To-Sales vs Fair Ratio: 8ZD is expensive based on its Price-To-Sales Ratio (8.9x) compared to the estimated Fair Price-To-Sales Ratio (2.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 8ZD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.84
€1.31
+54.6%
29.9%€2.14€0.98n/a6
May ’26€0.83
€1.31
+56.5%
29.9%€2.14€0.98n/a6
Apr ’26€0.98
€1.31
+33.3%
29.9%€2.14€0.98n/a6
Mar ’26€0.70
€1.13
+60.8%
58.7%€2.23€0.44n/a4
Feb ’26€0.57
€1.12
+96.6%
58.3%€2.19€0.44n/a4
Jan ’26€0.53
€1.12
+113.5%
58.3%€2.19€0.44n/a4
Dec ’25€0.54
€1.12
+108.4%
58.4%€2.18€0.44n/a4
Nov ’25€0.51
€1.04
+103.3%
60.0%€1.89€0.43n/a3
Oct ’25€0.42
€1.04
+144.6%
60.0%€1.89€0.43n/a3
Sep ’25€0.33
€1.04
+212.4%
60.0%€1.89€0.43n/a3
Aug ’25€0.32
€1.04
+220.1%
60.0%€1.89€0.43n/a3
Jul ’25€0.37
€1.04
+182.5%
59.7%€1.89€0.43n/a3
Jun ’25€0.34
€0.97
+181.3%
56.5%€1.88€0.42n/a4
May ’25€0.36
€0.97
+165.8%
56.5%€1.88€0.42€0.834
Apr ’25€0.31
€0.97
+214.2%
56.5%€1.88€0.42€0.984
Mar ’25€0.29
€0.93
+226.1%
54.0%€1.90€0.43€0.705
Feb ’25€0.25
€0.93
+268.3%
54.7%€1.91€0.43€0.575
Jan ’25n/a
€0.93
0%
54.7%€1.91€0.43€0.535
Dec ’24n/a
€0.86
0%
64.4%€1.92€0.38€0.545
Nov ’24n/a
€0.87
0%
70.9%€1.90€0.38€0.514
Oct ’24n/a
€0.87
0%
70.9%€1.90€0.38€0.424
Sep ’24n/a
€0.92
0%
61.5%€1.88€0.41€0.334
Aug ’24n/a
€0.78
0%
64.4%€1.75€0.38€0.325
Jul ’24n/a
€0.90
0%
63.4%€1.86€0.39€0.374
Jun ’24n/a
€0.90
0%
63.4%€1.86€0.39€0.344
May ’24n/a
€0.90
0%
64.1%€1.88€0.39€0.364
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
€1.21
Fair Value
30.1% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 01:47
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbisko Cayman Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited
null nullChina International Capital Corporation Limited